46 results on '"Azad, Taha"'
Search Results
2. Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies
- Author
-
Azad, Taha, Rezaei, Reza, Singaravelu, Ragunath, Pelin, Adrian, Boulton, Stephen, Petryk, Julia, Onsu, Kemal Alper, Martin, Nikolas T., Hoskin, Victoria, Ghahremani, Mina, Marotel, Marie, Marius, Ricardo, He, Xiaohong, Crupi, Mathieu J. F., Hoang, Huy-Dung, Nik-Akhtar, Abolfazl, Ahmadi, Mahsa, Zamani, Nika Kooshki, Golshani, Ashkan, Alain, Tommy, Greer, Peter, Ardolino, Michele, Dickinson, Bryan C., Tai, Lee-Hwa, Ilkow, Carolina S., and Bell, John C.
- Published
- 2023
- Full Text
- View/download PDF
3. A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection
- Author
-
Boulton, Stephen, Poutou, Joanna, Gill, Rida, Alluqmani, Nouf, He, Xiaohong, Singaravelu, Ragunath, Crupi, Mathieu J.F., Petryk, Julia, Austin, Bradley, Angka, Leonard, Taha, Zaid, Teo, Iris, Singh, Siddarth, Jamil, Rameen, Marius, Ricardo, Martin, Nikolas, Jamieson, Taylor, Azad, Taha, Diallo, Jean-Simon, Ilkow, Carolina S., and Bell, John C.
- Published
- 2023
- Full Text
- View/download PDF
4. Inhibition of exchange proteins directly activated by cAMP as a strategy for broad-spectrum antiviral development
- Author
-
Boulton, Stephen, Crupi, Mathieu J.F., Singh, Siddharth, Carter-Timofte, Madalina E., Azad, Taha, Organ, Bailey C., He, Xiaohong, Gill, Rida, Neault, Serge, Jamieson, Taylor, Dave, Jaahnavi, Kurmasheva, Naziia, Austin, Bradley, Petryk, Julia, Singaravelu, Ragunath, Huang, Ben Zhen, Franco, Noah, Babu, Kaaviya, Parks, Robin J., Ilkow, Carolina S., Olagnier, David, and Bell, John C.
- Published
- 2023
- Full Text
- View/download PDF
5. Industrial applications of immobilized nano-biocatalysts
- Author
-
Razzaghi, Mozhgan, Homaei, Ahmad, Vianello, Fabio, Azad, Taha, Sharma, Tanvi, Nadda, Ashok Kumar, Stevanato, Roberto, Bilal, Muhammad, and Iqbal, Hafiz M. N.
- Published
- 2022
- Full Text
- View/download PDF
6. Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy
- Author
-
Wedge, Marie-Eve, Jennings, Victoria A., Crupi, Mathieu J. F., Poutou, Joanna, Jamieson, Taylor, Pelin, Adrian, Pugliese, Giuseppe, de Souza, Christiano Tanese, Petryk, Julia, Laight, Brian J., Boileau, Meaghan, Taha, Zaid, Alluqmani, Nouf, McKay, Hayley E., Pikor, Larissa, Khan, Sarwat Tahsin, Azad, Taha, Rezaei, Reza, Austin, Bradley, He, Xiaohong, Mansfield, David, Rose, Elaine, Brown, Emily E. F., Crawford, Natalie, Alkayyal, Almohanad, Surendran, Abera, Singaravelu, Ragunath, Roy, Dominic G., Migneco, Gemma, McSweeney, Benjamin, Cottee, Mary Lynn, Jacobus, Egon J., Keller, Brian A., Yamaguchi, Takafumi N., Boutros, Paul C., Geoffrion, Michele, Rayner, Katey J., Chatterjee, Avijit, Auer, Rebecca C., Diallo, Jean-Simon, Gibbings, Derrick, tenOever, Benjamin R., Melcher, Alan, Bell, John C., and Ilkow, Carolina S.
- Published
- 2022
- Full Text
- View/download PDF
7. Rox8 promotes microRNA-dependent yki messenger RNA decay
- Author
-
Guo, Xiaowei, Sun, Yihao, Azad, Taha, van Rensburg, H. J. Janse, Luo, Jingjing, Yang, Shuai, Liu, Peng, Lv, Zhongwei, Zhan, Meixiao, Lu, Ligong, Zhou, Yingqun, Ma, Xianjue, Zhang, Xiaoping, Yang, Xiaolong, and Xue, Lei
- Published
- 2020
8. A gain-of-functional screen identifies the Hippo pathway as a central mediator of receptor tyrosine kinases during tumorigenesis
- Author
-
Azad, Taha, Nouri, Kazem, Janse van Rensburg, Helena J., Maritan, Sarah M., Wu, Liqing, Hao, Yawei, Montminy, Tess, Yu, Jihang, Khanal, Prem, Mulligan, Lois M., and Yang, Xiaolong
- Published
- 2020
- Full Text
- View/download PDF
9. Recent progress in combination therapy of oncolytic vaccinia virus.
- Author
-
Mirbahari, Seyedeh Nasim, Da Silva, Miles, Muñoz Zúñiga, Abril Ixchel, Zamani, Nika Kooshki, St-Laurent, Gabriel, Totonchi, Mehdi, and Azad, Taha
- Subjects
ONCOLYTIC virotherapy ,VACCINIA ,ONCOGENIC viruses ,CANCER treatment - Abstract
In recent years, oncolytic viruses have emerged as promising agents for treating various cancers. An oncolytic virus is a non-pathogenic virus that, due to genetic manipulation, tends to replicate in and cause lysis of cancerous cells while leaving healthy cells unaffected. Among these viruses, vaccinia virus is an attractive platform for use as an oncolytic platform due to its 190 Kb genome with a high capacity for encoding therapeutic payloads. Combining oncolytic VV therapy with other conventional cancer treatments has been shown to be synergistic andmore effective than monotherapies. Additionally, OVV can be used as a vector to deliver therapeutic payloads, alone or in combination with other treatments, to increase overall efficacy. Here, we present a comprehensive analysis of preclinical and clinical studies that have evaluated the efficacy of oncolytic vaccinia viruses in cancer immunotherapy. We discuss the outcomes of these studies, including tumor regression rates, overall survival benefits, and long-term responses. Moreover, we provide insights into the challenges and limitations associated with oncolytic vaccinia virus-based therapies, including immune evasion mechanisms, potential toxicities, and the development of resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Hydrogen peroxide sensitivity connects the activity of COX5A and NPR3 to the regulation of YAP1 expression.
- Author
-
Takallou, Sarah, Hajikarimlou, Maryam, Al-gafari, Mustafa, Wang, Jiashu, Jagadeesan, Sasi Kumar, Kazmirchuk, Thomas David Daniel, Moteshareie, Houman, Indrayanti, Alex Mulet, Azad, Taha, Holcik, Martin, Samanfar, Bahram, Smith, Myron, and Golshani, Ashkan
- Published
- 2024
- Full Text
- View/download PDF
11. Comparative Analysis of Cyclization Techniques in Stapled Peptides: Structural Insights into Protein–Protein Interactions in a SARS-CoV-2 Spike RBD/hACE2 Model System.
- Author
-
Ferková, Sára, Froehlich, Ulrike, Nepveu-Traversy, Marie-Édith, Murza, Alexandre, Azad, Taha, Grandbois, Michel, Sarret, Philippe, Lavigne, Pierre, and Boudreault, Pierre-Luc
- Subjects
PROTEIN-protein interactions ,PEPTIDES ,PEPTIDASE ,NUCLEAR magnetic resonance ,SARS-CoV-2 ,RING formation (Chemistry) - Abstract
Medicinal chemistry is constantly searching for new approaches to develop more effective and targeted therapeutic molecules. The design of peptidomimetics is a promising emerging strategy that is aimed at developing peptides that mimic or modulate the biological activity of proteins. Among these, stapled peptides stand out for their unique ability to stabilize highly frequent helical motifs, but they have failed to be systematically reported. Here, we exploit chemically diverse helix-inducing i, i + 4 constraints—lactam, hydrocarbon, triazole, double triazole and thioether—on two distinct short sequences derived from the N-terminal peptidase domain of hACE2 upon structural characterization and in silico alanine scan. Our overall objective was to provide a sequence-independent comparison of α-helix-inducing staples using circular dichroism (CD) and nuclear magnetic resonance (NMR) spectroscopy. We identified a 9-mer lactam stapled peptide derived from the hACE2 sequence (His34-Gln42) capable of reaching its maximal helicity of 55% with antiviral activity in bioreporter- and pseudovirus-based inhibition assays. To the best of our knowledge, this study is the first comprehensive investigation comparing several cyclization methods with the goal of generating stapled peptides and correlating their secondary structures with PPI inhibitions using a highly topical model system (i.e., the interaction of SARS-CoV-2 Spike RBD with hACE2). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Ornithine-induced increase of proline and polyamines contents in tobacco cells under salinity conditions
- Author
-
Ghahremani, Mina, Ghanati, Faezeh, Bernard, Francoise, Azad, Taha, Gholami, Morteza, and Safari, Masoumeh
- Published
- 2014
13. Peptides of a Feather: How Computation Is Taking Peptide Therapeutics under Its Wing.
- Author
-
Kazmirchuk, Thomas David Daniel, Bradbury-Jost, Calvin, Withey, Taylor Ann, Gessese, Tadesse, Azad, Taha, Samanfar, Bahram, Dehne, Frank, and Golshani, Ashkan
- Subjects
PEPTIDES ,MACHINE learning ,MOLECULAR dynamics ,ARTIFICIAL intelligence ,FEATHERS - Abstract
Leveraging computation in the development of peptide therapeutics has garnered increasing recognition as a valuable tool to generate novel therapeutics for disease-related targets. To this end, computation has transformed the field of peptide design through identifying novel therapeutics that exhibit enhanced pharmacokinetic properties and reduced toxicity. The process of in-silico peptide design involves the application of molecular docking, molecular dynamics simulations, and machine learning algorithms. Three primary approaches for peptide therapeutic design including structural-based, protein mimicry, and short motif design have been predominantly adopted. Despite the ongoing progress made in this field, there are still significant challenges pertaining to peptide design including: enhancing the accuracy of computational methods; improving the success rate of preclinical and clinical trials; and developing better strategies to predict pharmacokinetics and toxicity. In this review, we discuss past and present research pertaining to the design and development of in-silico peptide therapeutics in addition to highlighting the potential of computation and artificial intelligence in the future of disease therapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy.
- Author
-
Martin, Nikolas T., Crupi, Mathieu J. F., Taha, Zaid, Poutou, Joanna, Whelan, Jack T., Vallati, Sydney, Petryk, Julia, Marius, Ricardo, Austin, Bradley, Azad, Taha, Boulanger, Mason, Burgess, Tamara, Sanders, Ilson, Victoor, Camille, Dickinson, Bryan C., Diallo, Jean-Simon, Ilkow, Carolina S., and Bell, John C.
- Subjects
GENETIC engineering ,VACCINIA ,RNA polymerases ,GENE expression ,PEPTIDES ,POLYMERASES ,PLANT viruses - Abstract
The approval of different cytokines as anti-neoplastic agents has been challenged by dose-limiting toxicities. Although reducing dose levels affords improved tolerability, efficacy is precluded at these suboptimal doses. Strategies combining cytokines with oncolytic viruses have proven to elicit potent survival benefits in vivo, despite promoting rapid clearance of the oncolytic virus itself. Herein, we developed an inducible expression system based on a Split-T7 RNA polymerase for oncolytic poxviruses to regulate the spatial and temporal expression of a beneficial transgene. This expression system utilizes approved anti-neoplastic rapamycin analogues for transgene induction. This treatment regimen thus offers a triple anti-tumour effect through the oncolytic virus, the induced transgene, and the pharmacologic inducer itself. More specifically, we designed our therapeutic transgene by fusing a tumour-targeting chlorotoxin (CLTX) peptide to interleukin-12 (IL-12), and demonstrated that the constructs were functional and cancer-selective. We next encoded this construct into the oncolytic vaccinia virus strain Copenhagen (VV-iIL-12mCLTX), and were able to demonstrate significantly improved survival in multiple syngeneic murine tumour models through both localized and systemic virus administration, in combination with rapalogs. In summary, our findings demonstrate that rapalog-inducible genetic switches based on Split-T7 polymerase allow for regulation of the oncolytic virus-driven production of tumour-localized IL-12 for improved anti-cancer immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Split-luciferase complementary assay: applications, recent developments, and future perspectives
- Author
-
Azad, Taha, Tashakor, Amin, and Hosseinkhani, Saman
- Published
- 2014
- Full Text
- View/download PDF
16. Oscillation of apoptosome formation through assembly of truncated Apaf-1
- Author
-
Azad, Taha, Tashakor, Amin, Rahmati, Fereshteh, Hemmati, Roohullah, and Hosseinkhani, Saman
- Published
- 2015
- Full Text
- View/download PDF
17. computational approach to rapidly design peptides that detect SARS-CoV-2 surface protein S.
- Author
-
Hajikarimlou, Maryam, Hooshyar, Mohsen, Moutaoufik, Mohamed Taha, Aly, Khaled A, Azad, Taha, Takallou, Sarah, Jagadeesan, Sasi, Phanse, Sadhna, Said, Kamaledin B, Samanfar, Bahram, Bell, John C, Dehne, Frank, Babu, Mohan, and Golshani, Ashkan
- Published
- 2022
- Full Text
- View/download PDF
18. Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein.
- Author
-
Sadremomtaz, Afsaneh, Al-Dahmani, Zayana M., Ruiz-Moreno, Angel J., Monti, Alessandra, Chao Wang, Azad, Taha, Bell, John C., Doti, Nunzianna, Velasco-Velázquez, Marco A., de Jong, Debora, de Jonge, Jørgen, Smit, Jolanda, Dömling, Alexander, van Goor, Harry, and Groves, Matthew R.
- Published
- 2022
- Full Text
- View/download PDF
19. Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern.
- Author
-
Carter-Timofte, Madalina Elena, Arulanandam, Rozanne, Kurmasheva, Naziia, Fu, Kathy, Laroche, Geneviève, Taha, Zaid, van der Horst, Demi, Cassin, Lena, van der Sluis, Renée M., Palermo, Enrico, Di Carlo, Daniele, Jacobs, David, Maznyi, Glib, Azad, Taha, Singaravelu, Ragunath, Ren, Fanghui, Hansen, Anne Louise, Idorn, Manja, Holm, Christian K., and Jakobsen, Martin R.
- Published
- 2021
- Full Text
- View/download PDF
20. Rox8 promotes microRNA-dependent yki messenger RNA decay.
- Author
-
Xiaowei Guo, Yihao Sun, Azad, Taha, van Rensburg, H. J. Janse, Jingjing Luo, Shuai Yang, Peng Liu, Zhongwei Lv, Meixiao Zhan, Ligong Lu, Yingqun Zhou, Xianjue Ma, Xiaoping Zhang, Xiaolong Yang, and Lei Xue
- Subjects
MESSENGER RNA ,RNA-binding proteins ,MICRORNA ,COLLECTIVE action - Abstract
The Hippo pathway is an evolutionarily conserved regulator of organ growth and tumorigenesis. In Drosophila, oncogenic RasV12 cooperates with loss-of-cell polarity to promote Hippo pathwaydependent tumor growth. To identify additional factors that modulate this signaling, we performed a genetic screen utilizing the Drosophila RasV12/lgl-/- in vivo tumor model and identified Rox8, a RNA-binding protein (RBP), as a positive regulator of the Hippo pathway. We found that Rox8 overexpression suppresses whereas Rox8 depletion potentiates Hippo-dependent tissue overgrowth, accompanied by altered Yki protein level and target gene expression. Mechanistically, Rox8 directly binds to a target site located in the yki 3' UTR, recruits and stabilizes the targeting of miR-8-loaded RISC, which accelerates the decay of yki messenger RNA (mRNA). Moreover, TIAR, the human ortholog of Rox8, is able to promote the degradation of yki mRNA when introduced into Drosophila and destabilizes YAP mRNA in human cells. Thus, our study provides in vivo evidence that the Hippo pathway is posttranscriptionally regulated by the collaborative action of RBP and microRNA (miRNA), which may provide an approach for modulating Hippo pathwaymediated tumorigenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. Olfactory Epithelium as an Infinitive Source of Neural Stem Cells for Derivation of Inner Ear Hair Cells
- Author
-
Bahmani, Tahere, Gholami, Samira, Mostafaie, Ali, Karimi, Ebrahim, Hoseinkhani, Zohreh, Azad, Taha, Mahdizadeh, Hamid, and Mansouri, Kamran
- Subjects
Neural stem cells ,Células madre ,Differentiation ,Olfactory mucosa ,Rat ,Mucosa olfatoria ,vestibulocitos ,Hair cells ,Rata ,Diferenciacion - Abstract
Surgical techniques for treatment of sensory neural hearing loss (SNHL) have unpredictable outcomes and in recent years cell therapy investigated for treatment of SNHL. Olfactory epithelium proceed neurogenesis during life time and provide an easily accessible source of neural stem cells. So the aim of this study was isolating neural stem cells from olfactory epithelium of rat and differentiation of these cells into hair cells of inner ear in vitro. The epithelium tissue of olfactory mucosa of rats were removed and digested by collagenase H. The digested tissue was cultured in flasks in suspension forms to create spheres. Spheres were passaged and from passage 2 spheres selected for differentiation. At this stage cells of spheres isolated from each other and placed in flask containing defined differentiation medium. Cells at this stage cultured in adhesive form. Immunohistochemistry and RT-PCR were used for neural stem cells and hair cells identification. Spheres formed from olfactory epithelium culture and immunohistochemistry revealed that cells of spheres from passage one and two expressed the neural stem cells markers. After culture of isolated cells in differentiation medium, the morphology of cells begun to change. The cells presented neural cells projections and after 10 days the projections elongated more and interact to each other in multi layers. RT-PCR and immunohistochemistry revealed that differentiated cells expressed hair cells specific genes. In this study we showed that neural stem cells of olfactory epithelium can differentiate into hair cells of inner ear and therefore can be used for treatment of SNHL. Las técnicas quirúrgicas para el tratamiento de la pérdida auditiva neural sensorial (PANS) tienen resultados impredecibles y en los últimos años la terapia celular ha sido investigada para su tratamiento. El epitelio olfatorio se forma durante la neurogénesis y proporciona una fuente fácilmente accesible de células madre neurales. El objetivo de este estudio fue aislar las células madre neurales del epitelio olfativo de la rata y la diferenciación de estas células en vestibulocitos del oído interno in vitro. Se retiró el tejido del epitelio de la mucosa olfatoria de ratas y fue digerido con colagenasa H. El tejido se cultivó en forma de suspensión para crear esferas. Se seleccionaron dos esferas para la diferenciación. En esta fase, las células de esferas fueron aisladas unas de otras y colocadas en un medio de diferenciación definido. Células en esta etapa fueron cultivadas en forma adhesiva. Inmunohistoquímica y RT-PCR se utilizó para las células madre neurales y la identificación de células ciliadas. Las esferas formadas a partir del cultivo del epitelio olfatorio y la inmunohistoquímica revelaron que las células de esferas en etapas uno y dos expresaban los marcadores de células madre neurales. Se observaron cambios en la morfología de las células después del cultivo de células aisladas. RT-PCR e inmunohistoquímica revelaron que las células diferenciadas expresaron células específicas de gen de vestibulocitos. Se observó que las células madre neuronales de epitelio olfatorio puede diferenciarse en células en forma de cabello del oído interno y por lo tanto puede ser utilizado para el tratamiento de PANS.
- Published
- 2017
22. A kinome-wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion.
- Author
-
Nouri, Kazem, Azad, Taha, Lightbody, Elizabeth, Khanal, Prem, Nicol, Christopher J., and Xiaolong Yang
- Abstract
The Hippo pathway is an emerging signaling pathway that plays important roles in organ size control, tissue homeostasis, tumorigenesis, metastasis, drug resistance, and immune response. Although many regulators of the Hippo pathway have been reported, the extracellular stimuli and kinase regulators of the Hippo pathway remain largely unknown. To identify novel regulars of the Hippo pathway, in this study we created the first ultra-bright NanoLuc biosensor (BS) to monitor the activity of large tumor suppressor (LATS) kinase 1, a central player of the Hippo pathway. We show that this NanoLuc BS achieves significantly advanced sensitivity and stability both in vitro using purified proteins and in vivo in living cells and mice. Using this BS, we perform the first kinome-wide screen and identify many kinases regulating LATS and its effectors yes-associated protein (YAP) and transcriptional co-activator with PDZ- binding motif (TAZ). We also show for the first time that activation of receptor tyrosine kinase anaplastic lymphoma kinase (ALK) by its extracellular ligand family with sequence similarity (FAM)150 activates Hippo effector YAP/TAZ by increasing their nuclear translocation. Significantly, we show that constitutively active ALK induces tumorigenic phenotypes, such as increased cancer cell proliferation/colony formation via YAP/TAZ and elevated immune evasion via YAP/TAZ-programmed death-ligand 1 in breast and lung cancer cells. In summary, we have developed a new LATS BS for cancer biology and therapeutics research and uncovered a novel ALK-LATS-YAP/TAZ signaling axis that may play important roles in cancer and possibly other biologic processes. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
23. Luciferin-Regenerating Enzyme Mediates Firefly Luciferase Activation Through Direct Effects of D-Cysteine on Luciferase Structure and Activity.
- Author
-
Hemmati, Roohullah, Hosseinkhani, Saman, Sajedi, Reza H., Azad, Taha, Tashakor, Amin, Bakhtiari, Nuredin, and Ataei, Farangis
- Subjects
CYSTEINE ,SULFUR amino acids ,PHOTOACTIVATION ,PHOSPHOTRANSFERASES ,PHOTOOXIDATIVE stress ,PHOTOBIOCHEMISTRY ,PHOTOBIOLOGY ,PHOTOCHEMISTRY - Abstract
Luciferin-regenerating enzyme (LRE) contributes to in vitro recycling of D-luciferin. In this study, reinvestigation of the luciferase-based LRE assay is reported. Here, using quick change site-directed mutagenesis seven T-LRE (Lampyris turkestanicus LRE) mutants were constructed and the most functional mutant of T-LRE (T
69 R) was selected for this research and the effects of D- and L-cysteine on T69 R T-LRE-luciferase- coupled assay are examined. Our results demonstrate that bioluminescent signal of T69 R T-LRE-luciferase-coupled assay increases and then reach equilibrium state in the presence of 5 mM D-cysteine. In addition, results reveal that 5 mM D- and L-cysteine in the absence of T69 R T-LRE cause a significant increase in bioluminescence intensity of luciferase over a long time as well as decrease in decay rate. Based on activity measurements, far-UV CD analysis, ANS fluorescence and DLS (Dynamic light scattering) results, D-cysteine increases the activity of luciferase due to weak redox potential, antiaggregatory effects, induction of changes in conformational structure and kinetics properties. In conclusion, in spite of previous reports on the effect of LRE on luciferase bioluminescent intensity, the majority of increase in luciferase light output and time-course originate from the direct effects of D-cysteine on structure and activity of firefly luciferase. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
24. Oxidative stress‐induced YAP1 expression is regulated by NCE102, CDA2, and BCS1.
- Author
-
Takallou, Sarah, Hajikarimlou, Maryam, Al‐gafari, Mustafa, Wang, Jiashu, Jagadeesan, Sasi Kumar, Kazmirchuk, Thomas David Daniel, Arnoczki, Christina, Moteshareie, Houman, Said, Kamaledin B., Azad, Taha, Holcik, Martin, Samanfar, Bahram, Smith, Myron, and Golshani, Ashkan
- Subjects
- *
GENE expression , *GENETIC transcription , *REACTIVE oxygen species , *HYDROGEN peroxide , *BIOMOLECULES - Abstract
Maintaining cellular homeostasis in the face of stress conditions is vital for the overall well‐being of an organism. Reactive oxygen species (ROS) are among the most potent cellular stressors and can disrupt the internal redox balance, giving rise to oxidative stress. Elevated levels of ROS can severely affect biomolecules and have been associated with a range of pathophysiological conditions. In response to oxidative stress, yeast activator protein‐1 (Yap1p) undergoes post‐translation modification that results in its nuclear accumulation. YAP1 has a key role in oxidative detoxification by promoting transcription of numerous antioxidant genes. In this study, we identified previously undescribed functions for NCE102, CDA2, and BCS1 in YAP1 expression in response to oxidative stress induced by hydrogen peroxide (H2O2). Deletion mutant strains for these candidates demonstrated increased sensitivity to H2O2. Our follow‐up investigation linked the activity of these genes to YAP1 expression at the level of translation. Under oxidative stress, global cap‐dependent translation is inhibited, prompting stress‐responsive genes like YAP1 to employ alternative modes of translation. We provide evidence that NCE102, CDA2, and BCS1 contribute to cap‐independent translation of YAP1 under oxidative stress. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition.
- Author
-
Azad, Taha, Singaravelu, Ragunath, Brown, Emily E.F., Taha, Zaid, Rezaei, Reza, Arulanandam, Rozanne, Boulton, Stephen, Diallo, Jean-Simon, Ilkow, Carolina S., and Bell, John C.
- Subjects
- *
SARS-CoV-2 , *LUCIFERASES , *BIOSENSORS , *COVID-19 pandemic , *ANGIOTENSIN converting enzyme , *PROTEIN receptors - Abstract
As the COVID-19 pandemic continues, there is an imminent need for rapid diagnostic tools and effective antivirals targeting SARS-CoV-2. We have developed a novel bioluminescence-based biosensor to probe a key host-virus interaction during viral entry: the binding of SARS-CoV-2 viral spike (S) protein to its receptor, angiotensin-converting enzyme 2 (ACE2). Derived from Nanoluciferase binary technology (NanoBiT), the biosensor is composed of Nanoluciferase split into two complementary subunits, Large BiT and Small BiT, fused to the Spike S1 domain of the SARS-CoV-2 S protein and ACE2 ectodomain, respectively. The ACE2-S1 interaction results in reassembly of functional Nanoluciferase, which catalyzes a bioluminescent reaction that can be assayed in a highly sensitive and specific manner. We demonstrate the biosensor's large dynamic range, enhanced thermostability and pH tolerance. In addition, we show the biosensor's versatility towards the high-throughput screening of drugs which disrupt the ACE2-S1 interaction, as well as its ability to act as a surrogate virus neutralization assay. Results obtained with our biosensor correlate well with those obtained with a Spike-pseudotyped lentivirus assay. This rapid in vitro tool does not require infectious virus and should enable the timely development of antiviral modalities targeting SARS-CoV-2 entry. • NanoBiT-based biosensor of interactions between SARS-CoV-2 Spike S1 domain and ACE2. • Biosensor readily detects monoclonal antibodies blocking Spike S1-ACE2 interactions. • The assay produces results in line with pseudovirus-based assays. • Can act as a surrogate for SARS-CoV-2 neutralization assays. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. A High-Throughput NanoBiT-Based Serological Assay Detects SARS-CoV-2 Seroconversion.
- Author
-
Azad, Taha, Rezaei, Reza, Singaravelu, Ragunath, Jamieson, Taylor R., Crupi, Mathieu J. F., Surendran, Abera, Poutou, Joanna, Taklifi, Parisa, Cowan, Juthaporn, Cameron, Donald William, Ilkow, Carolina S., and Luong, John H. T.
- Subjects
- *
SARS-CoV-2 , *SEROCONVERSION , *COVID-19 , *ANTIBODY formation , *SHIP handling - Abstract
High-throughput detection strategies for antibodies against SARS-CoV-2 in patients recovering from COVID-19, or in vaccinated individuals, are urgently required during this ongoing pandemic. Serological assays are the most widely used method to measure antibody responses in patients. However, most of the current methods lack the speed, stability, sensitivity, and specificity to be selected as a test for worldwide serosurveys. Here, we demonstrate a novel NanoBiT-based serological assay for fast and sensitive detection of SARS-CoV-2 RBD-specific antibodies in sera of COVID-19 patients. This assay can be done in high-throughput manner at 384 samples per hour and only requires a minimum of 5 μL of serum or 10 ng of antibody. The stability of our NanoBiT reporter in various temperatures (4–42 °C) and pH (4–12) settings suggests the assay will be able to withstand imperfect shipping and handling conditions for worldwide seroepidemiologic surveillance in the post-vaccination period of the pandemic. Our newly developed rapid assay is highly accessible and may facilitate a more cost-effective solution for seroconversion screening as vaccination efforts progress. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces Trimerization.
- Author
-
Azad, Taha, Singaravelu, Ragunath, Crupi, Mathieu J.F., Jamieson, Taylor, Dave, Jaahnavi, Brown, Emily E.F., Rezaei, Reza, Taha, Zaid, Boulton, Stephen, Martin, Nikolas T., Surendran, Abera, Poutou, Joanna, Ghahremani, Mina, Nouri, Kazem, Whelan, Jack T., Duong, Jessie, Tucker, Sarah, Diallo, Jean-Simon, Bell, John C., and Ilkow, Carolina S.
- Subjects
- *
SARS-CoV-2 , *TRIMERIZATION , *DRUG design , *DRUG development - Abstract
The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic presents an urgent need for an effective vaccine. Molecular characterization of SARS-CoV-2 is critical to the development of effective vaccine and therapeutic strategies. In the present study, we show that the fusion of the SARS-CoV-2 spike protein receptor-binding domain to its transmembrane domain is sufficient to mediate trimerization. Our findings may have implications for vaccine development and therapeutic drug design strategies targeting spike trimerization. As global efforts for developing SARS-CoV-2 vaccines are rapidly underway, we believe this observation is an important consideration for identifying crucial epitopes of SARS-CoV-2. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
28. Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis.
- Author
-
Azad, Taha, Rezaei, Reza, Surendran, Abera, Singaravelu, Ragunath, Boulton, Stephen, Dave, Jaahnavi, Bell, John C., and Ilkow, Carolina S.
- Subjects
- *
CYTOKINES , *PROTEINS , *CARCINOGENESIS , *PHOSPHOTRANSFERASES , *PROTEIN-tyrosine kinases , *MITOGEN-activated protein kinases - Abstract
The Hippo pathway plays a critical role in tissue and organ growth under normal physiological conditions, and its dysregulation in malignant growth has made it an attractive target for therapeutic intervention in the fight against cancer. To date, its complex signaling mechanisms have made it difficult to identify strong therapeutic candidates. Hippo signaling is largely carried out by two main activated signaling pathways involving receptor tyrosine kinases (RTKs)—the RTK/RAS/PI3K and the RTK-RAS-MAPK pathways. However, several RTKs have also been shown to regulate this pathway to engage downstream Hippo effectors and ultimately influence cell proliferation. In this text, we attempt to review the diverse RTK signaling pathways that influence Hippo signaling in the context of oncogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
29. Identification of Celastrol as a Novel YAP-TEAD Inhibitor for Cancer Therapy by High Throughput Screening with Ultrasensitive YAP/TAZ–TEAD Biosensors.
- Author
-
Nouri, Kazem, Azad, Taha, Ling, Min, van Rensburg, Helena J. Janse, Pipchuk, Alexander, Shen, He, Hao, Yawei, Zhang, Jianmin, and Yang, Xiaolong
- Subjects
- *
CELL proliferation , *ANTINEOPLASTIC agents , *BIOSENSORS , *CELL lines , *PROTEINS , *TUMORS , *HIGH throughput screening (Drug development) , *CELL migration inhibition , *IN vitro studies , *CHEMICAL inhibitors , *PHARMACODYNAMICS - Abstract
The Hippo pathway has emerged as a key signaling pathway that regulates a broad range of biological functions, and dysregulation of the Hippo pathway is a feature of a variety of cancers. Given this, some have suggested that disrupting the interaction of the Hippo core component YAP and its paralog TAZ with transcriptional factor TEAD may be an effective strategy for cancer therapy. However, there are currently no clinically available drugs targeting the YAP/TAZ–TEAD interaction for cancer treatment. To facilitate screens for small molecule compounds that disrupt the YAP–TEAD interaction, we have developed the first ultra-bright NanoLuc biosensor to quantify YAP/TAZ–TEAD protein–protein interaction (PPI) both in living cells and also in vitro using biosensor fusion proteins purified from bacteria. Using this biosensor, we have performed an in vitro high throughput screen (HTS) of small molecule compounds and have identified and validated the drug Celastrol as a novel inhibitor of YAP/TAZ–TEAD interaction. We have also demonstrated that Celastrol can inhibit cancer cell proliferation, transformation, and cell migration. In this study, we describe a new inhibitor of the YAP/TAZ–TEAD interaction warranting further investigation and offer a novel biosensor tool for the discovery of other new Hippo-targeting drugs in future work. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
30. The Role of YAP and TAZ in Angiogenesis and Vascular Mimicry.
- Author
-
Azad, Taha, Ghahremani, Mina, and Yang, Xiaolong
- Subjects
- *
VASCULOGENIC mimicry , *NEOVASCULARIZATION , *CYTOSKELETON , *ORGANISTS , *BLOOD vessels , *HEMATOPOIESIS - Abstract
Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is a physiological process that begins in utero and continues throughout life in both good health and disease. Understanding the underlying mechanism in angiogenesis could uncover a new therapeutic approach in pathological angiogenesis. Since its discovery, the Hippo signaling pathway has emerged as a key player in controlling organ size and tissue homeostasis. Recently, new studies have discovered that Hippo and two of its main effectors, Yes-associated protein (YAP) and its paralog transcription activator with PDZ binding motif (TAZ), play critical roles during angiogenesis. In this review, we summarize the mechanisms by which YAP/TAZ regulate endothelial cell shape, behavior, and function in angiogenesis. We further discuss how YAP/TAZ function as part of developmental and pathological angiogenesis. Finally, we review the role of YAP/TAZ in tumor vascular mimicry and propose directions for future work. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
31. TAZ enhances mammary cell proliferation in 3D culture through transcriptional regulation of IRS1.
- Author
-
Janse van Rensburg, Helena J., Lai, Dulcie, Azad, Taha, Hao, Yawei, and Yang, Xiaolong
- Subjects
- *
CANCER cell proliferation , *GENETIC transcription regulation , *CELLULAR signal transduction , *BREAST cancer , *GENE expression - Abstract
Abstract WW domain-containing transcriptional regulator 1 (TAZ) is a transcriptional co-activator and effector of the Hippo signaling pathway. In certain breast cancer subtypes, Hippo signaling is dysregulated leading to activation of TAZ and altered expression of TAZ transcriptional targets. Over the past decade, we and others have found that TAZ transcriptionally regulates genes that affect multiple aspects of breast cancer cell behaviour. However, while cancer cell-intrinsic oncogenic functions of TAZ have emerged, less is known about whether TAZ might also contribute to tumourigenesis by sensitizing tumour cells to factors present in the tumour microenvironment or in systemic circulation. Here, we show that TAZ directly regulates the expression of insulin receptor substrate 1 (IRS1) in breast cancer cells. TAZ or IRS1 overexpression induces a similar proliferative transformation phenotype in MCF10A mammary epithelial cells. TAZ enhances IRS1 mRNA, protein levels and downstream signaling in MCF10A. Mechanistically, TAZ interacts with the IRS1 promoter through the TEAD family of transcription factors and enhances its activity. Critically, TAZ-induced IRS1 upregulation contributes to the proliferation of TAZ-overexpressing MCF10A in 3-dimensional (3D) Matrigel culture. Therefore, we offer compelling evidence that TAZ regulates signaling through the insulin pathway in breast cancer cells. These findings highlight an additional mechanism by which TAZ may promote breast cancer tumourigenesis and progression by modulating cancer cell responses to exogenously produced factors. Highlights • The Hippo pathway effector TAZ regulates IRS1 in mammary epithelial cells • TAZ activates the IRS1 promoter through TEAD transcription factors • TAZ and IRS1 enhance 3D proliferation of mammary epithelial cells in the presence or absence of supplemental insulin • TAZ increases proliferation of mammary epithelial cells in 3D culture through IRS1 upregulation [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
32. Comparative Analysis of Cyclization Techniques in Stapled Peptides: Structural Insights into Protein-Protein Interactions in a SARS-CoV-2 Spike RBD/hACE2 Model System.
- Author
-
Ferková S, Froehlich U, Nepveu-Traversy MÉ, Murza A, Azad T, Grandbois M, Sarret P, Lavigne P, and Boudreault PL
- Subjects
- Humans, Cyclization, Lactams, Peptides pharmacology, Triazoles, COVID-19, SARS-CoV-2
- Abstract
Medicinal chemistry is constantly searching for new approaches to develop more effective and targeted therapeutic molecules. The design of peptidomimetics is a promising emerging strategy that is aimed at developing peptides that mimic or modulate the biological activity of proteins. Among these, stapled peptides stand out for their unique ability to stabilize highly frequent helical motifs, but they have failed to be systematically reported. Here, we exploit chemically diverse helix-inducing i , i + 4 constraints-lactam, hydrocarbon, triazole, double triazole and thioether-on two distinct short sequences derived from the N-terminal peptidase domain of hACE2 upon structural characterization and in silico alanine scan. Our overall objective was to provide a sequence-independent comparison of α-helix-inducing staples using circular dichroism (CD) and nuclear magnetic resonance (NMR) spectroscopy. We identified a 9-mer lactam stapled peptide derived from the hACE2 sequence (His34-Gln42) capable of reaching its maximal helicity of 55% with antiviral activity in bioreporter- and pseudovirus-based inhibition assays. To the best of our knowledge, this study is the first comprehensive investigation comparing several cyclization methods with the goal of generating stapled peptides and correlating their secondary structures with PPI inhibitions using a highly topical model system (i.e., the interaction of SARS-CoV-2 Spike RBD with hACE2).
- Published
- 2023
- Full Text
- View/download PDF
33. Fatty acid transport protein inhibition sensitizes breast and ovarian cancers to oncolytic virus therapy via lipid modulation of the tumor microenvironment.
- Author
-
Surendran A, Jamalkhah M, Poutou J, Birtch R, Lawson C, Dave J, Crupi MJF, Mayer J, Taylor V, Petryk J, de Souza CT, Moodie N, Billingsley JL, Austin B, Cormack N, Blamey N, Rezaei R, McCloskey CW, Fekete EEF, Birdi HK, Neault S, Jamieson TR, Wylie B, Tucker S, Azad T, Vanderhyden B, Tai LH, Bell JC, and Ilkow CS
- Subjects
- Humans, Female, Tumor Microenvironment, Culture Media, Conditioned, Lipids, Oncolytic Virotherapy, Oncolytic Viruses physiology, Ovarian Neoplasms therapy
- Abstract
Introduction: Adipocytes in the tumour microenvironment are highly dynamic cells that have an established role in tumour progression, but their impact on anti-cancer therapy resistance is becoming increasingly difficult to overlook., Methods: We investigated the role of adipose tissue and adipocytes in response to oncolytic virus (OV) therapy in adipose-rich tumours such as breast and ovarian neoplasms., Results: We show that secreted products in adipocyte-conditioned medium significantly impairs productive virus infection and OV-driven cell death. This effect was not due to the direct neutralization of virions or inhibition of OV entry into host cells. Instead, further investigation of adipocyte secreted factors demonstrated that adipocyte-mediated OV resistance is primarily a lipid-driven phenomenon. When lipid moieties are depleted from the adipocyte-conditioned medium, cancer cells are re-sensitized to OV-mediated destruction. We further demonstrated that blocking fatty acid uptake by cancer cells, in a combinatorial strategy with virotherapy, has clinical translational potential to overcome adipocyte-mediated OV resistance., Discussion: Our findings indicate that while adipocyte secreted factors can impede OV infection, the impairment of OV treatment efficacy can be overcome by modulating lipid flux in the tumour milieu., Competing Interests: We declare that JB has an interest in Turnstone Biologics, which developed the oncolytic Maraba MG1 virus as an OV platform. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Surendran, Jamalkhah, Poutou, Birtch, Lawson, Dave, Crupi, Mayer, Taylor, Petryk, de Souza, Moodie, Billingsley, Austin, Cormack, Blamey, Rezaei, McCloskey, Fekete, Birdi, Neault, Jamieson, Wylie, Tucker, Azad, Vanderhyden, Tai, Bell and Ilkow.)
- Published
- 2023
- Full Text
- View/download PDF
34. CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOX.
- Author
-
Whelan JT, Singaravelu R, Wang F, Pelin A, Tamming LA, Pugliese G, Martin NT, Crupi MJF, Petryk J, Austin B, He X, Marius R, Duong J, Jones C, Fekete EEF, Alluqmani N, Chen A, Boulton S, Huh MS, Tang MY, Taha Z, Scut E, Diallo JS, Azad T, Lichty BD, Ilkow CS, and Bell JC
- Subjects
- Humans, Animals, Mice, Genetic Vectors genetics, Vaccinia virus, Immunotherapy, Poxviridae genetics, Neoplasms
- Abstract
Poxvirus vectors represent versatile modalities for engineering novel vaccines and cancer immunotherapies. In addition to their oncolytic capacity and immunogenic influence, they can be readily engineered to express multiple large transgenes. However, the integration of multiple payloads into poxvirus genomes by traditional recombination-based approaches can be highly inefficient, time-consuming and cumbersome. Herein, we describe a simple, cost-effective approach to rapidly generate and purify a poxvirus vector with multiple transgenes. By utilizing a simple, modular CRISPR/Cas9 assisted-recombinant vaccinia virus engineering (CARVE) system, we demonstrate generation of a recombinant vaccinia virus expressing three distinct transgenes at three different loci in less than 1 week. We apply CARVE to rapidly generate a novel immunogenic vaccinia virus vector, which expresses a bacterial diadenylate cyclase. This novel vector, STINGPOX, produces cyclic di-AMP, a STING agonist, which drives IFN signaling critical to the anti-tumor immune response. We demonstrate that STINGPOX can drive IFN signaling in primary human cancer tissue explants. Using an immunocompetent murine colon cancer model, we demonstrate that intratumoral administration of STINGPOX in combination with checkpoint inhibitor, anti-PD1, promotes survival post-tumour challenge. These data demonstrate the utility of CRISPR/Cas9 in the rapid arming of poxvirus vectors with therapeutic payloads to create novel immunotherapies., Competing Interests: JB and BL are scientific co-founders of Turnstone Biologics, which develops oncolytic vaccinia viruses. JD, MH, MT, and AP have worked for Turnstone Biologics. JB and BL are shareholders in Turnstone Biologics. JB, CI, RS, FW and BL are co-inventors on a patent regarding the expression of bacterial cyclases and their therapeutic utility in mammals. RS is currently employed by the Public Health Agency of Canada (PHAC). His contribution to the study described herein was conducted prior to his employment at PHAC. The work was not undertaken under the auspices of PHAC and does not represent the views of PHAC. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Whelan, Singaravelu, Wang, Pelin, Tamming, Pugliese, Martin, Crupi, Petryk, Austin, He, Marius, Duong, Jones, Fekete, Alluqmani, Chen, Boulton, Huh, Tang, Taha, Scut, Diallo, Azad, Lichty, Ilkow and Bell.)
- Published
- 2023
- Full Text
- View/download PDF
35. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
- Author
-
Crupi MJF, Taha Z, Janssen TJA, Petryk J, Boulton S, Alluqmani N, Jirovec A, Kassas O, Khan ST, Vallati S, Lee E, Huang BZ, Huh M, Pikor L, He X, Marius R, Austin B, Duong J, Pelin A, Neault S, Azad T, Breitbach CJ, Stojdl DF, Burgess MF, McComb S, Auer R, Diallo JS, Ilkow CS, and Bell JC
- Subjects
- Humans, Mice, Animals, Immune Checkpoint Inhibitors pharmacology, Immune Checkpoint Inhibitors therapeutic use, Immunotherapy, Vaccinia virus, Disease Models, Animal, Tumor Microenvironment, Oncolytic Viruses, Oncolytic Virotherapy, Colorectal Neoplasms therapy
- Abstract
Colorectal cancer is the third most diagnosed cancer and the second leading cause of cancer mortality worldwide, highlighting an urgent need for new therapeutic options and combination strategies for patients. The orchestration of potent T cell responses against human cancers is necessary for effective antitumour immunity. However, regression of a limited number of cancers has been induced by immune checkpoint inhibitors, T cell engagers (TCEs) and/or oncolytic viruses. Although one TCE has been FDA-approved for the treatment of hematological malignancies, many challenges exist for the treatment of solid cancers. Here, we show that TCEs targeting CEACAM5 and CD3 stimulate robust activation of CD4 and CD8-positive T cells in in vitro co-culture models with colorectal cancer cells, but in vivo efficacy is hindered by a lack of TCE retention in the tumour microenvironment and short TCE half-life, as demonstrated by HiBiT bioluminescent TCE-tagging technology. To overcome these limitations, we engineered Bispecific Engager Viruses, or BEVirs, a novel tumour-targeted vaccinia virus platform for intra-tumour delivery of these immunomodulatory molecules. We characterized virus-mediated TCE-secretion, TCE specificity and functionality from infected colorectal cancer cells and patient tumour samples, as well as TCE cytotoxicity in spheroid models, in the presence and absence of T cells. Importantly, we show regression of colorectal tumours in both syngeneic and xenograft mouse models. Our data suggest that a different profile of cytokines may contribute to the pro-inflammatory and immune effects driven by T cells in the tumour microenvironment to provide long-lasting immunity and abscopal effects. We establish combination regimens with immune checkpoint inhibitors for aggressive colorectal peritoneal metastases. We also observe a significant reduction in lung metastases of colorectal tumours through intravenous delivery of our oncolytic virus driven T-cell based combination immunotherapy to target colorectal tumours and FAP-positive stromal cells or CTLA4-positive T
reg cells in the tumour microenvironment. In summary, we devised a novel combination strategy for the treatment of colorectal cancers using oncolytic vaccinia virus to enhance immune-payload delivery and boost T cell responses within tumours., Competing Interests: We declare that JB has an interest in Turnstone Biologics, which develops the oncolytic vaccinia virus as an OV platform. LP, MH, JD, AP, CB, DS and MB have worked for Turnstone Biologics. JB, CB, DS and MB are shareholders in Turnstone Biologics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Crupi, Taha, Janssen, Petryk, Boulton, Alluqmani, Jirovec, Kassas, Khan, Vallati, Lee, Huang, Huh, Pikor, He, Marius, Austin, Duong, Pelin, Neault, Azad, Breitbach, Stojdl, Burgess, McComb, Auer, Diallo, Ilkow and Bell.)- Published
- 2022
- Full Text
- View/download PDF
36. Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen.
- Author
-
Taha Z, Arulanandam R, Maznyi G, Godbout E, Carter-Timofte ME, Kurmasheva N, Reinert LS, Chen A, Crupi MJF, Boulton S, Laroche G, Phan A, Rezaei R, Alluqmani N, Jirovec A, Acal A, Fekete EEF, Singaravelu R, Petryk J, Idorn M, Potts KG, Todesco H, John C, Mahoney DJ, Ilkow CS, Giguère P, Alain T, Côté M, Paludan SR, Olagnier D, Bell JC, Azad T, and Diallo JS
- Subjects
- Angiotensin-Converting Enzyme 2 antagonists & inhibitors, Animals, Mice, Protein Binding, Spike Glycoprotein, Coronavirus chemistry, United States, United States Food and Drug Administration, Antiviral Agents pharmacology, Imidazoles pharmacology, SARS-CoV-2 drug effects, COVID-19 Drug Treatment
- Abstract
We established a split nanoluciferase complementation assay to rapidly screen for inhibitors that interfere with binding of the receptor binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein with its target receptor, angiotensin-converting enzyme 2 (ACE2). After a screen of 1,200 US Food and Drug Administration (FDA)-approved compounds, we identified bifonazole, an imidazole-based antifungal agent, as a competitive inhibitor of RBD-ACE2 binding. Mechanistically, bifonazole binds ACE2 around residue K353, which prevents association with the RBD, affecting entry and replication of spike-pseudotyped viruses as well as native SARS-CoV-2 and its variants of concern (VOCs). Intranasal administration of bifonazole reduces lethality in K18-hACE2 mice challenged with vesicular stomatitis virus (VSV)-spike by 40%, with a similar benefit after live SARS-CoV-2 challenge. Our screen identified an antiviral agent that is effective against SARS-CoV-2 and VOCs such as Omicron that employ the same receptor to infect cells and therefore has high potential to be repurposed to control, treat, or prevent coronavirus disease 2019 (COVID-19)., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2022 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
37. A computational approach to rapidly design peptides that detect SARS-CoV-2 surface protein S.
- Author
-
Hajikarimlou M, Hooshyar M, Moutaoufik MT, Aly KA, Azad T, Takallou S, Jagadeesan S, Phanse S, Said KB, Samanfar B, Bell JC, Dehne F, Babu M, and Golshani A
- Abstract
The coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prompted the development of diagnostic and therapeutic frameworks for timely containment of this pandemic. Here, we utilized our non-conventional computational algorithm, InSiPS, to rapidly design and experimentally validate peptides that bind to SARS-CoV-2 spike (S) surface protein. We previously showed that this method can be used to develop peptides against yeast proteins, however, the applicability of this method to design peptides against other proteins has not been investigated. In the current study, we demonstrate that two sets of peptides developed using InSiPS method can detect purified SARS-CoV-2 S protein via ELISA and Surface Plasmon Resonance (SPR) approaches, suggesting the utility of our strategy in real time COVID-19 diagnostics. Mass spectrometry-based salivary peptidomics shortlist top SARS-CoV-2 peptides detected in COVID-19 patients' saliva, rendering them attractive SARS-CoV-2 diagnostic targets that, when subjected to our computational platform, can streamline the development of potent peptide diagnostics of SARS-CoV-2 variants of concern. Our approach can be rapidly implicated in diagnosing other communicable diseases of immediate threat., (© The Author(s) 2022. Published by Oxford University Press on behalf of NAR Genomics and Bioinformatics.)
- Published
- 2022
- Full Text
- View/download PDF
38. Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection.
- Author
-
Boulton S, Poutou J, Martin NT, Azad T, Singaravelu R, Crupi MJF, Jamieson T, He X, Marius R, Petryk J, Tanese de Souza C, Austin B, Taha Z, Whelan J, Khan ST, Pelin A, Rezaei R, Surendran A, Tucker S, Fekete EEF, Dave J, Diallo JS, Auer R, Angel JB, Cameron DW, Cailhier JF, Lapointe R, Potts K, Mahoney DJ, Bell JC, and Ilkow CS
- Subjects
- Animals, Mice, Antibodies, Neutralizing, Antibodies, Viral, COVID-19 Vaccines, Immunity, SARS-CoV-2 genetics, Spike Glycoprotein, Coronavirus, T-Lymphocytes, COVID-19 prevention & control, Vaccines
- Abstract
The coronavirus disease 2019 (COVID-19) pandemic requires the continued development of safe, long-lasting, and efficacious vaccines for preventive responses to major outbreaks around the world, and especially in isolated and developing countries. To combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we characterize a temperature-stable vaccine candidate (TOH-Vac1) that uses a replication-competent, attenuated vaccinia virus as a vector to express a membrane-tethered spike receptor binding domain (RBD) antigen. We evaluate the effects of dose escalation and administration routes on vaccine safety, efficacy, and immunogenicity in animal models. Our vaccine induces high levels of SARS-CoV-2 neutralizing antibodies and favorable T cell responses, while maintaining an optimal safety profile in mice and cynomolgus macaques. We demonstrate robust immune responses and protective immunity against SARS-CoV-2 variants after only a single dose. Together, these findings support further development of our novel and versatile vaccine platform as an alternative or complementary approach to current vaccines., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2021. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
39. Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter.
- Author
-
Rezaei R, Surendran A, Singaravelu R, Jamieson TR, Taklifi P, Poutou J, Azad T, and Ilkow CS
- Subjects
- COVID-19 Testing, Humans, Pandemics, Spike Glycoprotein, Coronavirus, Antibodies, Viral, COVID-19 diagnosis, COVID-19 immunology, SARS-CoV-2
- Abstract
The emergence of the COVID-19 pandemic has increased the need for better serological detection methods to determine the epidemiologic impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The increasing number of SARS-CoV-2 infections raises the need for better antibody detection assays. Current antibody detection methods compromise sensitivity for speed or are sensitive but time-consuming. A large proportion of SARS-CoV-2-neutralizing antibodies target the receptor-binding domain (RBD), one of the primary immunogenic compartments of SARS-CoV-2. We have recently designed and developed a highly sensitive, bioluminescent-tagged RBD (NanoLuc HiBiT-RBD) to detect SARS-CoV-2 antibodies. The following text describes the procedure to produce the HiBiT-RBD complex and a fast assay to evaluate the presence of RBD-targeting antibodies using this tool. Due to the durability of the HiBiT-RBD protein product over a wide range of temperatures and the shorter experimental procedure that can be completed within 1 h, the protocol can be considered as a more efficient alternative to detect SARS-CoV-2 antibodies in patient serum samples.
- Published
- 2021
- Full Text
- View/download PDF
40. Luciferase-Based Biosensors in the Era of the COVID-19 Pandemic.
- Author
-
Azad T, Janse van Rensburg HJ, Morgan J, Rezaei R, Crupi MJF, Chen R, Ghahremani M, Jamalkhah M, Forbes N, Ilkow C, and Bell JC
- Abstract
Luciferase-based biosensors have a wide range of applications and assay formats, including their relatively recent use in the study of viruses. Split luciferase, bioluminescence resonance energy transfer, circularly permuted luciferase, cyclic luciferase, and dual luciferase systems have all been used to interrogate the structure and function of prominent viruses infecting humans, animals, and plants. The utility of these assays is demonstrated by numerous studies which have not only successfully characterized interactions between viral and host cell proteins but that have also used these systems to identify viral inhibitors. In the present COVID-19 pandemic, luciferase-based biosensors are already playing a critical role in the study of the culprit virus SARS-CoV-2 as well as in the development of serological assays and drug development via high-throughput screening. In this review paper, we provide a summary of existing luciferase-based biosensors and their applications in virology., Competing Interests: The authors declare no competing financial interest., (© 2021 The Authors. Published by American Chemical Society.)
- Published
- 2021
- Full Text
- View/download PDF
41. Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection.
- Author
-
Jamieson TR, Poutou J, Marius R, He X, Rezaei R, Azad T, and Ilkow CS
- Subjects
- COVID-19 Vaccines immunology, Humans, Neutralization Tests, Vesicular stomatitis Indiana virus immunology, Antibodies, Neutralizing analysis, Antibodies, Viral analysis, COVID-19 immunology, COVID-19 Serological Testing methods, Optical Imaging methods, SARS-CoV-2 immunology, Spike Glycoprotein, Coronavirus immunology
- Abstract
As the COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, it has become evident that the presence of neutralizing antibodies against the virus may provide protection against future infection. Thus, as the creation and translation of effective COVID-19 vaccines continues at an unprecedented speed, the development of fast and effective methods to measure neutralizing antibodies against SARS-CoV-2 will become increasingly important to determine long-term protection against infection for both previously infected and immunized individuals. This paper describes a high-throughput protocol using vesicular stomatitis virus (VSV) pseudotyped with the SARS-CoV-2 spike protein to measure the presence of neutralizing antibodies in convalescent serum from patients who have recently recovered from COVID-19. The use of a replicating pseudotyped virus eliminates the necessity for a containment level 3 facility required for SARS-CoV-2 handling, making this protocol accessible to virtually any containment level 2 lab. The use of a 96-well format allows for many samples to be run at the same time with a short turnaround time of 24 h.
- Published
- 2021
- Full Text
- View/download PDF
42. Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry.
- Author
-
Azad T, Singaravelu R, Taha Z, Jamieson TR, Boulton S, Crupi MJF, Martin NT, Fekete EEF, Poutou J, Ghahremani M, Pelin A, Nouri K, Rezaei R, Marshall CB, Enomoto M, Arulanandam R, Alluqmani N, Samson R, Gingras AC, Cameron DW, Greer PA, Ilkow CS, Diallo JS, and Bell JC
- Subjects
- Angiotensin-Converting Enzyme 2 antagonists & inhibitors, Angiotensin-Converting Enzyme 2 genetics, Angiotensin-Converting Enzyme 2 immunology, Asparagine chemistry, Asparagine metabolism, Binding Sites, COVID-19 diagnosis, COVID-19 immunology, COVID-19 virology, Genes, Reporter, Glycosylation drug effects, HEK293 Cells, Host-Pathogen Interactions drug effects, Host-Pathogen Interactions genetics, Humans, Luciferases genetics, Luciferases metabolism, Luminescent Measurements, Protein Binding, Protein Interaction Domains and Motifs, Protein Structure, Secondary, Receptors, Virus antagonists & inhibitors, Receptors, Virus genetics, Receptors, Virus immunology, SARS-CoV-2 drug effects, SARS-CoV-2 growth & development, SARS-CoV-2 immunology, Spike Glycoprotein, Coronavirus antagonists & inhibitors, Spike Glycoprotein, Coronavirus genetics, Spike Glycoprotein, Coronavirus immunology, Virus Internalization drug effects, COVID-19 Drug Treatment, Angiotensin-Converting Enzyme 2 chemistry, Antibodies, Neutralizing pharmacology, Biological Assay, Lectins pharmacology, Receptors, Virus chemistry, Spike Glycoprotein, Coronavirus chemistry
- Abstract
The ongoing COVID-19 pandemic has highlighted the immediate need for the development of antiviral therapeutics targeting different stages of the SARS-CoV-2 life cycle. We developed a bioluminescence-based bioreporter to interrogate the interaction between the SARS-CoV-2 viral spike (S) protein and its host entry receptor, angiotensin-converting enzyme 2 (ACE2). The bioreporter assay is based on a nanoluciferase complementation reporter, composed of two subunits, large BiT and small BiT, fused to the S receptor-binding domain (RBD) of the SARS-CoV-2 S protein and ACE2 ectodomain, respectively. Using this bioreporter, we uncovered critical host and viral determinants of the interaction, including a role for glycosylation of asparagine residues within the RBD in mediating successful viral entry. We also demonstrate the importance of N-linked glycosylation to the RBD's antigenicity and immunogenicity. Our study demonstrates the versatility of our bioreporter in mapping key residues mediating viral entry as well as screening inhibitors of the ACE2-RBD interaction. Our findings point toward targeting RBD glycosylation for therapeutic and vaccine strategies against SARS-CoV-2., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2021. Published by Elsevier Inc.)
- Published
- 2021
- Full Text
- View/download PDF
43. Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction.
- Author
-
Brown EEF, Rezaei R, Jamieson TR, Dave J, Martin NT, Singaravelu R, Crupi MJF, Boulton S, Tucker S, Duong J, Poutou J, Pelin A, Yasavoli-Sharahi H, Taha Z, Arulanandam R, Surendran A, Ghahremani M, Austin B, Matar C, Diallo JS, Bell JC, Ilkow CS, and Azad T
- Subjects
- Amino Acid Sequence, Angiotensin-Converting Enzyme 2 genetics, Antibodies, Neutralizing immunology, Antiviral Agents pharmacology, Binding Sites, COVID-19 immunology, HEK293 Cells, Host Microbial Interactions, Humans, Models, Molecular, Mutation, Protein Binding, Protein Interaction Domains and Motifs, Receptors, Virus chemistry, Receptors, Virus metabolism, SARS-CoV-2 drug effects, Sequence Alignment, COVID-19 Drug Treatment, Angiotensin-Converting Enzyme 2 chemistry, Angiotensin-Converting Enzyme 2 metabolism, COVID-19 metabolism, COVID-19 virology, SARS-CoV-2 metabolism, Spike Glycoprotein, Coronavirus chemistry, Spike Glycoprotein, Coronavirus metabolism
- Abstract
Despite sequence similarity to SARS-CoV-1, SARS-CoV-2 has demonstrated greater widespread virulence and unique challenges to researchers aiming to study its pathogenicity in humans. The interaction of the viral receptor binding domain (RBD) with its main host cell receptor, angiotensin-converting enzyme 2 (ACE2), has emerged as a critical focal point for the development of anti-viral therapeutics and vaccines. In this study, we selectively identify and characterize the impact of mutating certain amino acid residues in the RBD of SARS-CoV-2 and in ACE2, by utilizing our recently developed NanoBiT technology-based biosensor as well as pseudotyped-virus infectivity assays. Specifically, we examine the mutational effects on RBD-ACE2 binding ability, efficacy of competitive inhibitors, as well as neutralizing antibody activity. We also look at the implications the mutations may have on virus transmissibility, host susceptibility, and the virus transmission path to humans. These critical determinants of virus-host interactions may provide more effective targets for ongoing vaccines, drug development, and potentially pave the way for determining the genetic variation underlying disease severity.
- Published
- 2021
- Full Text
- View/download PDF
44. Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor (LATS) Biosensor.
- Author
-
Azad T, Nouri K, Janse van Rensburg HJ, Hao Y, and Yang X
- Subjects
- Hippo Signaling Pathway, Humans, Signal Transduction, Biosensing Techniques methods, Protein Serine-Threonine Kinases genetics, Tumor Suppressor Proteins genetics
- Abstract
The Hippo signaling pathway is a conserved regulator of organ size and has important roles in the development and cancer biology. Due to technical challenges, it remains difficult to assess the activity of this signaling pathway and interpret it within a biological context. The existing literature on large tumor suppressor (LATS) relies on methods that are qualitative and cannot easily be scaled-up for screening. Recently, we have developed a bioluminescence-based biosensor to monitor the kinase activity of LATS-a core component of the Hippo kinase cascade. Here, we describe procedures for how this LATS biosensor (LATS-BS) can be used to characterize Hippo pathway regulators. First, we provide a detailed protocol for investigating the effect of an overexpressed protein candidate (e.g., VEGFR2) on LATS activity using the LATS-BS. Then, we show how the LATS-BS can be used for a small-scale kinase inhibitor screen. This protocol can feasibly be scaled-up to perform larger screens, which undoubtedly will identify novel regulators of the Hippo pathway.
- Published
- 2018
- Full Text
- View/download PDF
45. PI3K Positively Regulates YAP and TAZ in Mammary Tumorigenesis Through Multiple Signaling Pathways.
- Author
-
Zhao Y, Montminy T, Azad T, Lightbody E, Hao Y, SenGupta S, Asselin E, Nicol C, and Yang X
- Subjects
- Acyltransferases, Animals, Cell Cycle Proteins, Disease Models, Animal, Female, Humans, Mice, Signal Transduction, YAP-Signaling Proteins, Adaptor Proteins, Signal Transducing metabolism, Breast Neoplasms metabolism, Phosphatidylinositol 3-Kinases metabolism, Phosphoproteins metabolism, Transcription Factors metabolism
- Abstract
Breast cancer is a leading cause of death in women worldwide. Active mutations of PI3K catalytic subunit PIK3CA (e.g., H1047R) and amplification of its homolog PIK3CB are observed in a large number of breast cancers. In recent years, aberrant activation of Transcriptional coactivator with PDZ binding motif (TAZ) and its paralog Yes-associated protein (YAP) have also been found to be important for breast cancer development and progression. However, whether PI3K interacts with YAP/TAZ during mammary tumorigenesis is unknown. Through a systematic gain-of-function screen for kinases involved in mammary tumorigenesis, we identified PIK3CB as a transformation-inducing kinase in breast cells. We further determined that PIK3CB positively regulates YAP and TAZ to promote transformation and inhibit mammary cell death in vitro PIK3CB coexpression with TAZ, rather than PIK3CB or TAZ alone, in human MCF10A nontumorigenic mammary cells is sufficient for tumor formation in mice in vivo Interestingly, we also determined that PIK3CA-H1047R enhances YAP and TAZ activity in mammary tumorigenesis in vitro Mechanistically, the regulation of YAP/TAZ by both PIK3CA and PIK3CB occurs through multiple signaling pathways including LATS-dependent and LATS-independent pathways. Therefore, in this study, we determine that PI3K and YAP/TAZ interact to promote breast cancer cell transformation. Implications: This study provides the first evidence that the Hippo pathway effectors TAZ and YAP are critical mediators of PI3K-induced mammary tumorigenesis and synergistically function together with PI3K in transformation of mammary cells. These findings may provide a novel rationale for targeting YAP/TAZ alone or in combination with PI3K inhibitors for breast cancer therapy in the future. Mol Cancer Res; 16(6); 1046-58. ©2018 AACR ., (©2018 American Association for Cancer Research.)
- Published
- 2018
- Full Text
- View/download PDF
46. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
- Author
-
Janse van Rensburg HJ, Azad T, Ling M, Hao Y, Snetsinger B, Khanal P, Minassian LM, Graham CH, Rauh MJ, and Yang X
- Subjects
- Adaptor Proteins, Signal Transducing genetics, Animals, B7-H1 Antigen genetics, B7-H1 Antigen metabolism, Cell Line, Tumor, Gene Expression Profiling methods, Gene Expression Regulation, Neoplastic, Hippo Signaling Pathway, Humans, Intracellular Signaling Peptides and Proteins genetics, Mice, Phosphoproteins genetics, Phosphoproteins metabolism, Promoter Regions, Genetic, Protein Serine-Threonine Kinases genetics, T-Lymphocytes physiology, Trans-Activators, Transcription Factors genetics, Transcriptional Coactivator with PDZ-Binding Motif Proteins, YAP-Signaling Proteins, Adaptor Proteins, Signal Transducing metabolism, B7-H1 Antigen immunology, Intracellular Signaling Peptides and Proteins metabolism, Protein Serine-Threonine Kinases metabolism, Signal Transduction, Transcription Factors metabolism, Tumor Escape genetics
- Abstract
The Hippo pathway component WW domain-containing transcription regulator 1 (TAZ) is a transcriptional coactivator and an oncogene in breast and lung cancer. Transcriptional targets of TAZ that modulate immune cell function in the tumor microenvironment are poorly understood. Here, we perform a comprehensive screen for immune-related genes regulated by TAZ and its paralog YAP using NanoString gene expression profiling. We identify the immune checkpoint molecule PD-L1 as a target of Hippo signaling. The upstream kinases of the Hippo pathway, mammalian STE20-like kinase 1 and 2 (MST1/2), and large tumor suppressor 1 and 2 (LATS1/2), suppress PD-L1 expression while TAZ and YAP enhance PD-L1 levels in breast and lung cancer cell lines. PD-L1 expression in cancer cell lines is determined by TAZ activity and TAZ/YAP/TEAD increase PD-L1 promoter activity. Critically, TAZ-induced PD-L1 upregulation in human cancer cells is sufficient to inhibit T-cell function. The relationship between TAZ and PD-L1 is not conserved in multiple mouse cell lines, likely due to differences between the human and mouse PD-L1 promoters. To explore the extent of divergence in TAZ immune-related targets between human and mouse cells, we performed a second NanoString screen using mouse cell lines. We show that many targets of TAZ may be differentially regulated between these species. These findings highlight the role of Hippo signaling in modifying human/murine physiologic/pathologic immune responses and provide evidence implicating TAZ in human cancer immune evasion. Significance: Human-specific activation of PD-L1 by a novel Hippo signaling pathway in cancer immune evasion may have a significant impact on research in immunotherapy. Cancer Res; 78(6); 1457-70. ©2018 AACR ., (©2018 American Association for Cancer Research.)
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.